ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

NCT03183128 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

BIOLOGICAL: SER-109
DRUG: Placebo

Sponsor

Seres Therapeutics, Inc.